Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Orthocell Ltd ( (AU:OCC) ) has shared an update.
Orthocell Limited has achieved a third consecutive quarter of record revenue, reporting $2.21 million for the December 2024 quarter, marking a 9% increase from the previous quarter and a 46% increase from the same period last year. This growth is attributed to the increasing market traction of its products, Striate+ and Remplir, across existing markets and the potential expansion into new markets, including the anticipated FDA approval for Remplir in the US. With a strong cash position and strategic partnerships, Orthocell is well-positioned to capitalize on significant growth opportunities in the global market.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company specializing in the development of medical devices such as Striate+ for dental bone regeneration and Remplir for peripheral nerve repair. The company has a strong focus on global market expansion, targeting a significant market opportunity estimated at approximately US$4.5 billion across key regions including the USA, Europe, UK, Australia, New Zealand, and Asia. Orthocell collaborates with major distributors like BioHorizons and Device Technologies to enhance the reach of its products.
YTD Price Performance: -1.85%
Average Trading Volume: 1,519,782
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$318.8M
Learn more about OCC stock on TipRanks’ Stock Analysis page.